ts-143
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 24, 2015 (NCT03591133)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
EGLN2 unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03595202 | Phase 1 | Apr 3, 2017 | Taisho Pharmaceutical |
| NCT03581071 | Phase 1 | Oct 6, 2016 | Taisho Pharmaceutical |
| NCT03591133 | Phase 1 | Dec 24, 2015 | Taisho Pharmaceutical |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Taisho Pharmaceutical | For profit | 3 | 3 | 1 | 2015 |
1 organizations
Page 1 / 1